Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 9,145 matching trials from the live ClinicalTrials.gov search.
Filters: Rochester, Minnesota Clear all
Terminated Phase 3 Interventional Results available

CleanUP IPF for the Pulmonary Trials Cooperative

NCT02759120
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Antimicrobial therapy: Co-trimoxazole or Doxycycline, No Intervention: Standard of Care
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 9, 2026, 5:58 PM EST
Completed Phase 2 Interventional Results available

Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease

NCT00074035
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
pentostatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
16
States / cities
Lewes, Delaware • Newark, Delaware • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Nov 9, 2026, 5:58 PM EST
Active, not recruiting No phase listed Observational

Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer

NCT04856046
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 9, 2026, 5:58 PM EST
Completed No phase listed Observational

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01142427
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
17,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
214
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Nov 9, 2026, 5:58 PM EST
Recruiting Not applicable Interventional

The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction

NCT05109208
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Ulrasound Vibroelastography (UVE)
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 9, 2026, 5:58 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891
View directory record Official record
Conditions
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 9, 2026, 5:58 PM EST
Completed Early Phase 1 Interventional

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

NCT00470379
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
resiquimod
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Nov 9, 2026, 5:58 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

NCT00912496
View directory record Official record
Conditions
Influenza
Interventions
MF-59, A/Anhui/05, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
637 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Nov 9, 2026, 5:58 PM EST
Completed Phase 2Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients

NCT00638703
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
Oxalobacter formigenes, Placebo
Biological · Drug
Lead sponsor
OxThera
Industry
Eligibility
5 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Nov 9, 2026, 5:58 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cohort Study of Pancreatic Cancer Risk

NCT04247503
View directory record Official record
Conditions
Familial Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 9, 2026, 5:58 PM EST
Completed No phase listed Observational

Assessing the Patient Experience in Cancer Care

NCT01621295
View directory record Official record
Conditions
Brain Neoplasm, Breast Neoplasm, Endocrine Gland Neoplasm, Gastrointestinal Neoplasm, Genitourinary Neoplasm, Gynecological Neoplasm, Head and Neck Neoplasm, Lung Neoplasm, Melanoma, Sarcoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Nov 9, 2026, 5:58 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Qualitative Techniques to Define Meaningful Within-Patient Change in Symptoms of Advanced Cancer Patients

NCT06104657
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Nov 9, 2026, 5:58 PM EST
Active, not recruiting Phase 2 Interventional Results available

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

NCT03371719
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Apalutamide, External Beam Radiation Therapy, Placebo Administration
Drug · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
352
States / cities
Gilbert, Arizona • Peoria, Arizona • Scottsdale, Arizona + 251 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 9, 2026, 5:58 PM EST
Active, not recruiting Phase 2 Interventional Results available

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02595892
View directory record Official record
Conditions
Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Berzosertib, Gemcitabine, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 9, 2026, 5:58 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

St. John's Wort for Tobacco Cessation

NCT00405912
View directory record Official record
Conditions
Smoking, Nicotine Dependence
Interventions
Placebo, St. John's Wort-900 mg/day, St. John's Wort-1800mg/day
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Nov 9, 2026, 5:58 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus

NCT01288612
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Sedated Endoscopy, Transnasal Endoscopy
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 95 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Nov 9, 2026, 5:58 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

NCT00630032
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, Docetaxel, epirubicin hydrochloride, fluorouracil, ixabepilone
Drug
Lead sponsor
UNICANCER
Other
Eligibility
18 Years and older · Female only
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
17
States / cities
Scottsdale, Arizona • Denver, Colorado • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Nov 9, 2026, 5:58 PM EST
Completed Early Phase 1 Interventional

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01747798
View directory record Official record
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions
auranofin, laboratory biomarker analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Nov 9, 2026, 5:58 PM EST
Recruiting Phase 1Phase 2 Interventional

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT07477639
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions
TRX319, Bendamustine
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 9, 2026, 5:58 PM EST
Completed Phase 2 Interventional

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT05005728
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
Combination Product · Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
26
States / cities
Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 9, 2026, 5:58 PM EST
Completed Phase 2 Interventional Results available

Regorafenib in Metastatic Colorectal Cancer

NCT02466009
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Regorafenib
Drug
Lead sponsor
University of Rochester
Other
Eligibility
70 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Rochester, Minnesota • Rochester, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Nov 9, 2026, 5:58 PM EST
Completed Not applicable Interventional

Exercise for Fibromyalgia

NCT01253395
View directory record Official record
Conditions
Fibromyalgia
Interventions
Strength training, Aerobic exercise
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
72 participants
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2010 · Synced Nov 9, 2026, 5:58 PM EST
Active, not recruiting Phase 2 Interventional

Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia

NCT05677919
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Pirtobrutinib, Positron Emission Tomography, Venetoclax, Echocardiography, Multigated Acquisition Scan, Biopsy
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Nov 9, 2026, 5:58 PM EST
Completed Phase 3 Interventional

Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

NCT00105300
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
46
States / cities
Huntsville, Alabama • Roseville, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Nov 9, 2026, 5:58 PM EST